Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers
Open Access
- 1 January 2012
- journal article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 2, 194
- https://doi.org/10.3389/fonc.2012.00194
Abstract
Technological advances now allow us to rapidly produce CARs and other antibody-derived therapeutics targeting cell surface receptors. To maximize the potential of these new technologies, relevant extracellular targets must be identified. The Pediatric Oncology Branch of the NCI curates a freely accessible database of gene expression data for both pediatric cancers and normal tissues, through which we have defined discrete sets of over-expressed transcripts in twelve pediatric cancer subtypes as compared to normal tissues. We coupled gene expression profiles to current annotation databases (i.e., Affymetrix, Gene Ontology, Entrez Gene), in order to categorize transcripts by their subcellular location. In this manner we generated a list of potential immune targets expressed on the cell surface, ranked by their difference from normal tissue. Global differences from normal between each of the pediatric tumor types studied varied, indicating that some malignancies expressed transcript sets that were more highly diverged from normal tissues than others. The validity of our approach is seen by our findings for pre-B cell ALL, where targets currently in clinical trials were top-ranked hits (CD19, CD22). For some cancers, reagents already in development could potentially be applied to a new disease class, as exemplified by CD30 expression on sarcomas. Moreover, several potential new targets shared among several pediatric solid tumors are herein identified, such as MCAM (MUC18), MTDH (metadherin), and GPC2 (glypican-2). These targets have been identified at the mRNA level and are yet to be validated at the protein level. The safety of targeting these antigens has yet to be demonstrated and therefore the identified transcripts should be considered preliminary candidates for new CAR and therapeutic antibody targets. Prospective candidate targets will be evaluated by proteomic analysis including Westerns and immunohistochemistry of normal and tumor tissues.Keywords
This publication has 59 references indexed in Scilit:
- Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine ProductionThe Journal of Immunology, 2011
- GP369, an FGFR2-IIIb–Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 SignalingCancer Research, 2010
- Global Genomic and Proteomic Analysis Identifies Biological Pathways Related to High-Risk NeuroblastomaJournal of Proteome Research, 2009
- Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary originBMC Biology, 2009
- Potentiation of Proliferation of Some But Not All Human Colon Carcinoma Cell Lines by Immobilized Hepatic Asialoglycoprotein Receptor 1Oncology Research, 2009
- An integrated cross-platform prognosis study on neuroblastoma patientsGenomics, 2008
- Chemokine-like factor expression in the idiopathic inflammatory myopathiesActa Neurologica Scandinavica, 2008
- Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignanciesHaematologica, 2007
- Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysisProceedings of the National Academy of Sciences, 2004
- Metadherin, a cell surface protein in breast tumors that mediates lung metastasisCancer Cell, 2004